UBS AM
LCTX icon

UBS AM’s Lineage Cell Therapeutics LCTX Stock Holding History

UBS AM’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-46,519
Closed -$60.9K – 2866
2019
Q1 		$60.9K Buy
46,519
+10,318
+29% +$12.8K ﹤0.01% 2599
2018
Q4 		$33.1K Sell
36,201
-5,177
-13% -$7.93K ﹤0.01% 2603
2018
Q3 		$85.1K Hold
41,378
– – ﹤0.01% 2536
2018
Q2 		$74.6K Hold
41,378
– – ﹤0.01% 2569
2018
Q1 		$97.4K Buy
41,378
+28,575
+223% +$67K ﹤0.01% 2460
2017
Q4 		$24.1K Buy
+12,803
New +$28K ﹤0.01% 2470

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
PGP
Prescott General Partners Boca Raton, Florida $1.96B AUM 58.65% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Axa
Axa Paris, France $91.9M AUM 27.41% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

UBS AM's LCTX Position: Q2 2019 in Review

UBS AM sold out of Lineage Cell Therapeutics (LCTX) in Q2 2019, closing a stake of 46,519 shares — an estimated $60.9K sold.

UBS AM first reported a position in LCTX in Q4 2017 and held it in 6 quarters. The position peaked at $97.4K in Q1 2018. 107 funds tracked by Wall St. Rank hold LCTX as of Q2 2019.

  • UBS AM reported no remaining Lineage Cell Therapeutics position as of Q2 2019 after selling out during the quarter.
  • UBS AM sold 46,519 Lineage Cell Therapeutics shares in Q2 2019, an estimated $60.9K.
  • UBS AM first reported a position in Lineage Cell Therapeutics in Q4 2017 and held it in 6 quarters.
  • UBS AM's Lineage Cell Therapeutics position peaked at $97.4K in Q1 2018.
  • 107 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2019.

Based on UBS AM's 13F filing for Q2 2019, filed 15 Aug 2019.